Cognition Therapeutics Cash And Cash Equivalents As Of September 30, 2023, Were Approximately $33.0 Million, And Total Grant Funds Remaining From The NIA Were $74.3 Million, Expected To Provide Cash Runway Through November Of 2024
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics reported cash and cash equivalents of approximately $33.0 million as of September 30, 2023. The company also has remaining grant funds of $74.3 million from the National Institute on Aging (NIA), which are expected to provide a cash runway through November 2024.
November 02, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cognition Therapeutics' financial position appears stable with a cash runway through November 2024, thanks to its cash reserves and remaining NIA grant funds.
The company's cash and cash equivalents, along with the remaining grant funds from the NIA, provide a solid financial foundation for the company's operations through November 2024. This financial stability could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100